Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Geron Corporation (GERN)
USD1.42
-0.08 (-5.33%)
US NASDAQ Healthcare Biotechnology
Address
919 East Hillsdale Boulevard 94404
Foster City, CA, US
Foster City, CA, US
CEO
Harout Semerjian
Website
geron.com
IPO
1996-07-31
CIK 886744 ISIN US3741631036
Also trades on
London Stock Exchange · 0IV3.L (USD)
NASDAQ Global Select · GERN (USD)
Description
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.42
-0.08 (-5.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
16M
Beta
0.60
Float Shares
510.80M
Free Float %
79.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.72% | -10.26% | -16.17% | -14.11% | +12.90% | +6.06% | +9.38% | -54.84% | +1.45% | -46.77% | -80.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
1.42
Low
4.00
+181.7%
Consensus
5.89
+314.8%
Median
6.00
+322.5%
High
8.00
+463.4%
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 11 |
5.64
+297.2%
|
Quality scores
Altman Z-Score
-2.06
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+138.8% ★ Q1'26: +30.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+51.9% ★ Q1'26: +82.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-83.3% Q1'26: -121.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-28.9% Q1'26: -0.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-45.2% Q1'26: -0.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.2% ★ Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.85× Q1'26: 699.55× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.62M
est: 11.22M (-32.1%)
|
2.80M
est: 2.73M (+2.8%)
|
1.73M
est: 1.71M (+0.8%)
|
3.56M
est: 3.48M (+2.5%)
|
36.37M
est: 36.47M (-0.3%)
|
6.16M
est: 6.21M (-0.7%)
|
1.07M
est: 1.15M (-7.2%)
|
1.07M
est: 831.3K (+28.2%)
|
460.0K
est: 364.4K (+26.2%)
|
253.0K
est: 243.7K (+3.8%)
|
1.39M
est: 424.2K (+228.4%)
|
596.0K
est: 604.3K (-1.4%)
|
237.0K
est: 1.37M (-82.7%)
|
76.99M
est: 91.14M (-15.5%)
|
183.88M
est: 186.29M (-1.3%)
|
233.75M
231.62M – 237.66M
+25.5% YoY
|
333.13M
304.55M – 389.87M
+42.5% YoY
|
486.17M
452.27M – 550.87M
+45.9% YoY
|
697.46M
648.82M – 790.27M
+43.5% YoY
|
918.71M
854.64M – 1.04B
+31.7% YoY
|
| EBITDA |
-62.84M
est: -32.51M (-93.3%)
|
-59.91M
est: -55.67M (-7.6%)
|
-68.29M
est: -63.84M (-7.0%)
|
-109.67M
est: -96.78M (-13.3%)
|
803.0K
est: -13.42M (+106.0%)
|
-30.57M
est: -6.21M (-392.5%)
|
-29.18M
est: -1.15M (-2,441.7%)
|
-26.96M
est: -831.3K (-3,142.7%)
|
-72.44M
est: -364.4K (-19,779.5%)
|
-76.76M
est: -243.7K (-31,400.0%)
|
-111.59M
est: -424.2K (-26,205.8%)
|
-134.15M
est: -106.41M (-26.1%)
|
-174.78M
est: -1.18M (-14,763.2%)
|
-154.85M
est: -78.06M (-98.4%)
|
-51.92M
est: -159.56M (+67.5%)
|
-200.20M
-203.55M – -198.38M
-25.5% YoY
|
-285.32M
-333.91M – -260.84M
-42.5% YoY
|
-416.39M
-471.80M – -387.36M
-45.9% YoY
|
-597.36M
-676.84M – -555.70M
-43.5% YoY
|
-786.85M
-891.55M – -731.97M
-31.7% YoY
|
| EBIT |
-62.84M
est: -71.54M (+12.2%)
|
-67.04M
est: -68.01M (+1.4%)
|
-70.23M
est: -66.17M (-6.1%)
|
-111.28M
est: -98.15M (-13.4%)
|
134.0K
est: -14.07M (+101.0%)
|
-30.65M
est: -6.21M (-393.8%)
|
-29.26M
est: -1.15M (-2,448.3%)
|
-27.02M
est: -831.3K (-3,149.8%)
|
-72.51M
est: -364.4K (-19,797.1%)
|
-76.91M
est: -243.7K (-31,464.8%)
|
-112.37M
est: -424.2K (-26,390.3%)
|
-135.02M
est: -107.55M (-25.5%)
|
-175.82M
est: -1.18M (-14,828.2%)
|
-156.07M
est: -78.18M (-99.6%)
|
-53.13M
est: -159.80M (+66.8%)
|
-200.50M
-203.86M – -198.68M
-25.5% YoY
|
-285.75M
-334.42M – -261.24M
-42.5% YoY
|
-417.03M
-472.52M – -387.95M
-45.9% YoY
|
-598.27M
-677.88M – -556.55M
-43.5% YoY
|
-788.05M
-892.91M – -733.09M
-31.7% YoY
|
| Net Income |
-36.70M
est: -34.64M (-5.9%)
|
-62.02M
est: -58.17M (-6.6%)
|
-70.18M
est: -65.68M (-6.9%)
|
-111.38M
est: -98.44M (-13.1%)
|
46.0K
est: -13.55M (+100.3%)
|
-29.54M
est: -119.52M (+75.3%)
|
-27.92M
est: -109.83M (+74.6%)
|
-27.02M
est: -101.21M (+73.3%)
|
-68.55M
est: -271.33M (+74.7%)
|
-75.62M
est: -169.05M (+55.3%)
|
-116.11M
est: -217.07M (+46.5%)
|
-141.90M
est: -171.04M (+17.0%)
|
-184.13M
est: -219.55M (+16.1%)
|
-174.57M
est: -88.01M (-98.4%)
|
-85.78M
est: -67.31M (-27.4%)
|
-13.95M
-23.33M – -7.78M
+79.3% YoY
|
46.56M
21.67M – 99.67M
+433.7% YoY
|
146.69M
-40.00M – 413.33M
+215.1% YoY
|
283.33M
257.65M – 332.34M
+93.2% YoY
|
426.66M
387.98M – 500.47M
+50.6% YoY
|
| SGA |
15.84M
est: 1.11B (-98.6%)
|
16.18M
est: 270.09M (-94.0%)
|
14.34M
est: 169.63M (-91.5%)
|
18.04M
est: 344.35M (-94.8%)
|
17.79M
est: 15.63M (+13.9%)
|
18.76M
est: 614.75M (-96.9%)
|
19.29M
est: 113.71M (-83.0%)
|
18.71M
est: 82.35M (-77.3%)
|
21.69M
est: 36.10M (-39.9%)
|
27.11M
est: 24.14M (+12.3%)
|
29.67M
est: 42.02M (-29.4%)
|
43.63M
est: 59.86M (-27.1%)
|
69.14M
est: 106.81M (-35.3%)
|
145.73M
est: 7.09B (-97.9%)
|
159.26M
est: 14.49B (-98.9%)
|
18.18B
18.02B – 18.49B
+25.5% YoY
|
25.92B
23.69B – 30.33B
+42.5% YoY
|
37.82B
35.18B – 42.85B
+45.9% YoY
|
54.26B
50.47B – 61.48B
+43.5% YoY
|
71.47B
66.48B – 80.98B
+31.7% YoY
|
| EPS |
-0.49
est: -0.82 (+39.9%)
|
-0.79
est: -0.73 (-8.2%)
|
-0.80
est: -0.74 (-8.1%)
|
-1.14
est: -0.75 (-52.0%)
|
0.00
est: 0.00 (-92.5%)
|
-0.19
est: -0.19 (-2.7%)
|
-0.18
est: -0.17 (-5.9%)
|
-0.15
est: -0.16 (+4.3%)
|
-0.33
est: -0.42 (+21.4%)
|
-0.28
est: -0.26 (-7.0%)
|
-0.37
est: -0.34 (-10.1%)
|
-0.37
est: -0.38 (+3.5%)
|
-0.32
est: -0.36 (+11.4%)
|
-0.27
est: -0.25 (-7.0%)
|
-0.13
est: -0.10 (-30.0%)
|
-0.02
-0.03 – -0.01
+76.7% YoY
|
0.07
0.03 – 0.15
+378.6% YoY
|
0.19
-0.06 – 0.62
+192.3% YoY
|
0.43
0.39 – 0.50
+123.7% YoY
|
0.64
0.58 – 0.75
+50.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-117.53M
OE per share TTM
-0.18
Owner's Yield
-11.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
69
Total invested
18.03M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RTW Investments, LP | 44.11M | 7.30% | — | 44.11M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 2 | Roderick Wong, M.D. | 44.11M | 7.30% | — | 44.11M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 3 | Peter Kolchinsky | 32.39M | 9.99% | — | 32.39M | — | 32.39M | HC, IN | — | 2022-02-14 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 32.39M | 9.99% | — | 32.39M | — | 32.39M | PN | — | 2022-02-14 | ↗ |
| 5 | RA Capital Management, L.P. | 32.39M | 9.99% | — | 32.39M | — | 32.39M | IA, PN | — | 2022-02-14 | ↗ |
| 6 | Rajeev Shah | 32.39M | 9.99% | — | 32.39M | — | 32.39M | HC, IN | — | 2022-02-14 | ↗ |
| 7 | The Vanguard Group - 23-1945930 | 28.56M | 5.26% | — | 777.6K | 27.41M | 1.16M | IA | Pennsylvania | 2024-02-13 | ↗ |
| 8 | (1) BlackRock, Inc. | 25.22M | 7.80% | 24.47M | — | 25.22M | — | HC | Delaware | 2022-02-01 | ↗ |
| 9 | David Kroin | 24.02M | 5.35% | — | 24.02M | — | — | HC, IN | Delaware | 2023-01-13 | ↗ |
| 10 | Deep Track Biotechnology Master Fund, Ltd. | 24.02M | 5.35% | — | 24.02M | — | — | CO | Delaware | 2023-01-13 | ↗ |
| 11 | Deep Track Capital, LP | 24.02M | 5.35% | — | 24.02M | — | — | IA, OO | Delaware | 2023-01-13 | ↗ |
| 12 | Mr. David Kroin | 23.10M | 7.30% | — | 23.10M | — | — | HC, IN | USA | 2020-06-01 | ↗ |
| 13 | Vivo Opportunity, LLC | 22.86M | 5.90% | 22.86M | — | 22.86M | — | OO | Delaware | 2022-04-08 | ↗ |
| 14 | 17 GP, LLC | 20.19M | 9.60% | — | 20.19M | — | 20.19M | OO | — | 2020-06-04 | ↗ |
| 15 | Ali Behbahani | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 16 | Anthony A. Florence, Jr. | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 17 | Carmen Chang | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 18 | Edward T. Mathers | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 19 | Forest Baskett | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 20 | Growth Equity Opportunities 17, LLC | 20.19M | 9.60% | — | 20.19M | — | 20.19M | OO | — | 2020-06-04 | ↗ |
| 21 | H. Makhzoumi | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 22 | Joshua Makower | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 23 | Landsman | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 24 | NEA Partners 17, L.P. | 20.19M | 9.60% | — | 20.19M | — | 20.19M | PN | — | 2020-06-04 | ↗ |
| 25 | New Enterprise Associates 17, L.P. | 20.19M | 9.60% | — | 20.19M | — | 20.19M | PN | — | 2020-06-04 | ↗ |
| 26 | Rick Yang | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 27 | Scott D. Sandell | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 28 | W. Sonsini | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 29 | Walker | 20.19M | 9.60% | — | 20.19M | — | 20.19M | IN | — | 2020-06-04 | ↗ |
| 30 | STATE STREET CORPORATION | 19.71M | 5.17% | — | 18.98M | — | 19.71M | HC | BOSTON, MASSACHUSETTS | 2023-02-01 | ↗ |
| 31 | Dr. Jeffrey R. Jay, M.D. | 12.75M | 4.00% | — | 12.75M | — | — | HC, IN | USA | 2021-02-16 | ↗ |
| 32 | Great Point Partners, LLC | 12.75M | 4.00% | — | 12.75M | — | — | IA, OO | USA | 2021-02-16 | ↗ |
| 33 | Mr. Ortav Yehudai | 12.75M | 4.00% | — | 12.75M | — | — | HC, IN | USA | 2021-02-16 | ↗ |
| 34 | EcoR1 Capital, LLC | 9.62M | 11.00% | — | 9.62M | — | 9.62M | IA, OO | — | 2022-02-14 | ↗ |
| 35 | Oleg Nodelman | 9.62M | 11.00% | — | 9.62M | — | 9.62M | HC, IN | — | 2022-02-14 | ↗ |
| 36 | EcoR1 Capital Fund Qualified, L.P. | 8.75M | 11.00% | — | 8.75M | — | 8.75M | PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
69
-197 vs prev Q
New positions
6
Closed positions
196
Increased
25
Reduced
12
Put/Call ratio
0.00
Calls held
9.5K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 63.77M +3.4M (+5.6%) | 84.18M +1.5M (+1.8%) | 9.56% +0.496 pp | 0.86% -0.157 pp | USD1.84 -28.3% | 23 qtrs — |
| 2 | BLACKROCK, INC. | 45.91M -692.4K (-1.5%) | 60.61M -3.2M (-5.1%) | 6.88% -0.114 pp | 0.00% 0.000 pp | USD4.46 -70.4% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 35.66M +1.2M (+3.6%) | 47.07M -87.2K (-0.2%) | 5.35% +0.178 pp | 0.00% +0.000 pp | USD2.38 -44.5% | 84 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 32.51M -8.6M (-20.9%) | 42.91M -13.4M (-23.8%) | 4.87% -1.296 pp | 0.77% -0.806 pp | USD1.63 -19.0% | 13 qtrs — |
| 5 | VIVO CAPITAL, LLC | 27.23M +— (+0.0%) | 35.94M -1.4M (-3.6%) | 4.08% -0.006 pp | 2.32% -0.679 pp | USD1.91 -30.9% | 16 qtrs — |
| 6 | STATE STREET CORP | 26.87M +248.5K (+0.9%) | 35.46M -1.0M (-2.8%) | 4.03% +0.032 pp | 0.00% 0.000 pp | USD2.62 -49.6% | 51 qtrs — |
| 7 | SOLEUS CAPITAL MANAGEMENT, L.P. | 23.29M +6.0M (+34.7%) | 30.74M +7.1M (+29.8%) | 3.49% +0.896 pp | 1.13% -0.058 pp | USD1.40 -5.7% | 4 qtrs — |
| 8 | EVERSEPT PARTNERS, LP | 17.66M +5.1M (+40.2%) | 23.31M +6.1M (+35.1%) | 2.65% +0.756 pp | 1.17% -0.015 pp | USD1.37 -3.6% | 3 qtrs — |
| 9 | GOLDMAN SACHS GROUP INC | 16.17M -5.1M (-24.1%) | 21.35M -7.8M (-26.9%) | 2.42% -0.774 pp | 0.00% -0.001 pp | USD2.37 -44.3% | 73 qtrs — |
| 10 | CLEARBRIDGE INVESTMENTS, LLC | 14.24M +18.0K (+0.1%) | 18.80M -687.5K (-3.5%) | 2.14% 0.000 pp | 0.02% +0.000 pp | USD1.52 -13.2% | 4 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 13.03M -96.2K (-0.7%) | 17.20M -782.1K (-4.3%) | 1.95% -0.017 pp | 0.00% 0.000 pp | USD2.46 -46.3% | 78 qtrs — |
| 12 | MORGAN STANLEY | 12.60M +1.9M (+17.8%) | 16.64M +2.0M (+13.5%) | 1.89% +0.283 pp | 0.00% +0.000 pp | USD2.88 -54.2% | 51 qtrs — |
| 13 | VESTAL POINT CAPITAL, LP | 11.32M -5.9M (-34.3%) | 14.94M -8.7M (-36.7%) | 1.70% -0.889 pp | 0.51% -0.558 pp | USD2.52 -47.6% | 8 qtrs — |
| 14 | CITADEL ADVISORS LLC | 9.93M -5.8M (-36.8%) | 13.10M -8.4M (-39.1%) | 1.49% -0.870 pp | 0.00% -0.001 pp | USD2.13 -38.0% | 52 qtrs — |
| 15 | ABRDN PLC | 9.53M +3.6M (+59.6%) | 12.58M +4.4M (+53.7%) | 1.43% +0.532 pp | 0.02% +0.007 pp | USD1.89 -30.2% | 6 qtrs — |
| 16 | NANTAHALA CAPITAL MANAGEMENT, LLC | 9.03M +— (+0.0%) | 11.91M -451.3K (-3.6%) | 1.35% -0.002 pp | 0.39% -0.036 pp | USD1.37 -3.6% | 2 qtrs — |
| 17 | FMR LLC | 8.08M +375.9K (+4.9%) | 10.66M +111.1K (+1.1%) | 1.21% +0.055 pp | 0.00% +0.000 pp | USD2.28 -42.1% | 58 qtrs — |
| 18 | WOODLINE PARTNERS LP | 7.50M +1.6M (+27.5%) | 9.91M +1.8M (+22.9%) | 1.12% +0.242 pp | 0.04% +0.000 pp | USD3.33 -60.4% | 8 qtrs — |
| 19 | DEUTSCHE BANK AG\ | 5.14M +10.5K (+0.2%) | 6.79M -242.6K (-3.5%) | 0.77% +0.001 pp | 0.00% 0.000 pp | USD1.66 -20.5% | 50 qtrs — |
| 20 | SEGALL BRYANT & HAMILL, LLC | 5.05M -286.3K (-5.4%) | 6.66M -644.7K (-8.8%) | 0.76% -0.044 pp | 0.09% -0.007 pp | USD3.18 -58.5% | 11 qtrs — |
| 21 | PALE FIRE CAPITAL SE | 4.79M +2.5M (+109.9%) | 6.32M +3.2M (+102.2%) | 0.72% +0.375 pp | 0.42% +0.082 pp | USD1.34 -1.5% | 2 qtrs — |
| 22 | NORTHERN TRUST CORP | 4.73M -136.0K (-2.8%) | 6.24M -422.6K (-6.3%) | 0.71% -0.021 pp | 0.00% 0.000 pp | USD2.39 -44.8% | 51 qtrs — |
| 23 | MILLENNIUM MANAGEMENT LLC | 4.60M -6.8M (-59.5%) | 6.08M -9.5M (-61.0%) | 0.69% -1.016 pp | 0.00% -0.004 pp | USD1.98 -33.3% | 24 qtrs — |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.51M +4.6K (+0.1%) | 5.96M -219.4K (-3.6%) | 0.68% 0.000 pp | 0.00% 0.000 pp | USD2.38 -44.5% | 100 qtrs — |
| 25 | ALGERT GLOBAL LLC | 3.50M -1.0M (-22.7%) | 4.62M -1.6M (-25.5%) | 0.52% -0.155 pp | 0.07% -0.032 pp | USD1.85 -28.6% | 7 qtrs — |
| 26 | KYNAM CAPITAL MANAGEMENT, LP | 3.46M +— (+0.0%) | 4.56M -172.8K (-3.6%) | 0.52% -0.001 pp | 0.29% -0.061 pp | USD1.59 -17.0% | 4 qtrs — |
| 27 | UBS GROUP AG | 3.27M -4.4M (-57.6%) | 4.32M -6.3M (-59.1%) | 0.49% -0.668 pp | 0.00% -0.001 pp | USD2.30 -42.6% | 45 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 3.11M -1.6M (-34.2%) | 4.10M -2.4M (-36.6%) | 0.47% -0.243 pp | 0.00% -0.003 pp | USD2.18 -39.4% | 14 qtrs — |
| 29 | CANDRIAM S.C.A. | 2.84M -414.5K (-12.7%) | 3.75M -709.6K (-15.9%) | 0.43% -0.063 pp | 0.02% -0.005 pp | USD1.50 -12.0% | 4 qtrs — |
| 30 | TWO SIGMA INVESTMENTS, LP | 2.80M +949.5K (+51.3%) | 3.70M +1.2M (+45.7%) | 0.42% +0.142 pp | 0.01% +0.001 pp | USD1.35 -2.2% | 2 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 2.70M -796.3K (-22.8%) | 3.56M -1.2M (-25.6%) | 0.40% -0.120 pp | 0.00% 0.000 pp | USD2.43 -45.7% | 52 qtrs — |
| 32 | EDMOND DE ROTHSCHILD HOLDING S.A. | 2.33M +— (+0.0%) | 3.08M -116.5K (-3.6%) | 0.35% -0.001 pp | 0.04% -0.006 pp | USD3.85 -65.7% | 6 qtrs — |
| 33 | NUVEEN, LLC | 2.00M +25.1K (+1.3%) | 2.64M -65.7K (-2.4%) | 0.30% +0.003 pp | 0.00% +0.000 pp | USD1.59 -17.0% | 4 qtrs — |
| 34 | BARCLAYS PLC | 1.58M +275.5K (+21.2%) | 2.08M -3.8M (-64.8%) | 0.24% +0.041 pp | 0.00% -0.001 pp | USD2.33 -43.3% | 51 qtrs — |
| 35 | BANK OF NEW YORK MELLON CORP | 1.57M -908.0 (-0.1%) | 2.08M -79.9K (-3.7%) | 0.24% -0.001 pp | 0.00% +0.000 pp | USD3.12 -57.7% | 66 qtrs — |
| 36 | AFFINITY ASSET ADVISORS, LLC | 1.50M +— (+0.0%) | 1.98M -75.0K (-3.6%) | 0.22% 0.000 pp | 0.11% -0.066 pp | USD3.29 -59.9% | 8 qtrs — |
| 37 | NAN FUNG TRINITY (HK) LTD | 1.37M +— (+0.0%) | 1.81M -68.7K (-3.6%) | 0.21% 0.000 pp | 0.14% -0.044 pp | USD1.41 -6.4% | 3 qtrs — |
| 38 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.30M +55.5K (+4.5%) | 1.71M +11.2K (+0.7%) | 0.19% +0.008 pp | 0.00% +0.000 pp | USD2.25 -41.3% | 51 qtrs — |
| 39 | UBS ASSET MANAGEMENT AMERICAS INC | 1.23M -80.6K (-6.1%) | 1.63M -172.0K (-9.6%) | 0.18% -0.012 pp | 0.00% +0.000 pp | USD2.71 -51.3% | 49 qtrs — |
| 40 | INVESCO LTD. | 1.23M +265.2K (+27.6%) | 1.62M +302.0K (+23.0%) | 0.18% +0.040 pp | 0.00% +0.000 pp | USD1.78 -25.8% | 24 qtrs — |
| 41 | HRT FINANCIAL LP | 1.20M +298.4K (+33.1%) | 1.58M +349.0K (+28.3%) | 0.18% +0.045 pp | 0.01% +0.001 pp | USD1.54 -14.3% | 5 qtrs — |
| 42 | SQUAREPOINT OPS LLC | 1.13M -2.2M (-65.6%) | 1.49M -3.0M (-66.9%) | 0.17% -0.324 pp | 0.00% -0.003 pp | USD1.51 -12.6% | 14 qtrs — |
| 43 | PENSIONMARK FINANCIAL GROUP, LLC | 1.03M -6.0K (-0.6%) | 1.36M -59.9K (-4.2%) | 0.16% -0.001 pp | 0.02% -0.007 pp | USD4.49 -70.6% | 10 qtrs — |
| 44 | JANE STREET GROUP, LLC | 1.01M -1.1M (-52.3%) | 1.34M -1.6M (-54.0%) | 0.15% -0.167 pp | 0.00% 0.000 pp | USD1.39 -5.0% | 23 qtrs — |
| 45 | SWISS NATIONAL BANK | 926.1K +— (+0.0%) | 1.22M -46.3K (-3.6%) | 0.14% 0.000 pp | 0.00% +0.000 pp | USD2.74 -51.8% | 49 qtrs — |
| 46 | ALMITAS CAPITAL LLC | 896.3K -50.0K (-5.3%) | 1.18M -113.3K (-8.7%) | 0.13% -0.008 pp | 0.26% -0.036 pp | USD1.37 -3.6% | 2 qtrs — |
| 47 | WELLS FARGO & COMPANY/MN | 855.1K +85.9K (+11.2%) | 1.13M +74.9K (+7.1%) | 0.13% +0.013 pp | 0.00% +0.000 pp | USD1.95 -32.3% | 57 qtrs — |
| 48 | MML INVESTORS SERVICES, LLC | 834.1K +283.0K (+51.4%) | 1.10M +346.0K (+45.8%) | 0.13% +0.042 pp | 0.00% +0.001 pp | USD2.57 -48.6% | 11 qtrs — |
| 49 | RAFFERTY ASSET MANAGEMENT, LLC | 821.9K -164.5K (-16.7%) | 1.08M -266.4K (-19.7%) | 0.12% -0.025 pp | 0.00% -0.001 pp | USD2.85 -53.7% | 22 qtrs — |
| 50 | STONEPINE CAPITAL MANAGEMENT, LLC | 805.8K -794.2K (-49.6%) | 1.06M -1.1M (-51.5%) | 0.12% -0.119 pp | 0.78% -1.005 pp | USD1.45 -9.0% | 4 qtrs — |
| 51 | — | 777.9K +777.9K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.12% +0.117 pp | 0.78% +0.781 pp | USD1.32 +0.0% | 1 qtrs NEW |
| 52 | RENAISSANCE TECHNOLOGIES LLC | 737.2K -1.6M (-68.8%) | 973.1K -2.3M (-70.0%) | 0.11% -0.244 pp | 0.00% -0.003 pp | USD2.10 -37.1% | 7 qtrs — |
| 53 | RHUMBLINE ADVISERS | 727.5K -110.1K (-13.1%) | 960.3K -187.3K (-16.3%) | 0.11% -0.017 pp | 0.00% 0.000 pp | USD2.36 -44.1% | 51 qtrs — |
| 54 | CENTIVA CAPITAL, LP | 686.5K +686.5K (+100.0%) | 906.2K +906.2K (+100.0%) | 0.10% +0.103 pp | 0.01% +0.007 pp | USD1.32 +0.0% | 4 qtrs — |
| 55 | AMERIPRISE FINANCIAL INC | 651.6K -45.5K (-6.5%) | 860.1K -94.9K (-9.9%) | 0.10% -0.007 pp | 0.00% +0.000 pp | USD4.04 -67.3% | 11 qtrs — |
| 56 | SRS CAPITAL ADVISORS, INC. | 627.3K -766.8K (-55.0%) | 828.0K -1.1M (-57.1%) | 0.09% -0.115 pp | 0.02% -0.004 pp | USD1.37 -3.6% | 2 qtrs — |
| 57 | LION POINT CAPITAL, LP | 578.0K +78.0K (+15.6%) | 763.0K +78.0K (+11.4%) | 0.09% +0.012 pp | 3.95% +0.057 pp | USD2.97 -55.6% | 8 qtrs — |
| 58 | ALPS ADVISORS INC | 524.2K +221.7K (+73.3%) | 691.9K +277.5K (+66.9%) | 0.08% +0.033 pp | 0.00% +0.002 pp | USD1.37 -3.6% | 3 qtrs — |
| 59 | VIRTUS INVESTMENT ADVISERS, INC. | 502.5K +217.6K (+76.4%) | 663.3K +273.0K (+70.0%) | 0.08% +0.033 pp | 0.18% +0.069 pp | USD1.40 -5.7% | 4 qtrs — |
| 60 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 475.3K -4.2K (-0.9%) | 627.3K -29.5K (-4.5%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD2.20 -40.0% | 52 qtrs — |
| 61 | LEGAL & GENERAL GROUP PLC | 443.3K -64.6K (-12.7%) | 585.2K -110.6K (-15.9%) | 0.07% -0.010 pp | 0.00% +0.000 pp | USD2.76 -52.2% | 46 qtrs — |
| 62 | HENNION & WALSH ASSET MANAGEMENT, INC. | 421.5K +57.1K (+15.7%) | 556.3K +57.1K (+11.4%) | 0.06% +0.009 pp | 0.02% +0.001 pp | USD3.86 -65.8% | 7 qtrs — |
| 63 | PRIVATE ADVISOR GROUP, LLC | 420.3K +1.5K (+0.3%) | 554.8K -19.0K (-3.3%) | 0.06% +0.000 pp | 0.00% 0.000 pp | USD1.88 -29.8% | 16 qtrs — |
| 64 | ALLIANCEBERNSTEIN L.P. | 386.3K -239.0K (-38.2%) | 510.0K -346.7K (-40.5%) | 0.06% -0.036 pp | 0.00% 0.000 pp | USD3.57 -63.0% | 61 qtrs — |
| 65 | TWO SIGMA ADVISERS, LP | 365.0K -20.5K (-5.3%) | 481.9K -46.3K (-8.8%) | 0.05% -0.003 pp | 0.00% 0.000 pp | USD1.37 -3.6% | 2 qtrs — |
| 66 | INSPIRE INVESTING, LLC | 354.2K +25.1K (+7.6%) | 467.5K +16.7K (+3.7%) | 0.05% +0.004 pp | 0.04% -0.002 pp | USD2.07 -36.2% | 10 qtrs — |
| 67 | LOS ANGELES CAPITAL MANAGEMENT LLC | 364.2K -12.1K (-3.2%) | 451.6K -63.9K (-12.4%) | 0.05% -0.002 pp | 0.00% 0.000 pp | USD1.66 -20.5% | 6 qtrs — |
| 68 | ADAR1 CAPITAL MANAGEMENT, LLC | 336.2K -120.0K (-26.3%) | 443.8K -181.2K (-29.0%) | 0.05% -0.018 pp | 0.03% -0.026 pp | USD3.21 -58.9% | 9 qtrs — |
| 69 | PRICE T ROWE ASSOCIATES INC /MD/ | 312.0K +23.2K (+8.0%) | 412.0K +16.0K (+4.0%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD3.58 -63.1% | 75 qtrs — |
| 70 | PROFUND ADVISORS LLC | 306.9K +93.4K (+43.8%) | 405.1K +112.7K (+38.5%) | 0.05% +0.014 pp | 0.01% +0.003 pp | USD2.38 -44.5% | 12 qtrs — |
| 71 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 301.6K -2.6K (-0.9%) | 399.1K -14.7K (-3.5%) | 0.05% -0.001 pp | 0.00% 0.000 pp | USD4.30 -69.3% | 7 qtrs — |
| 72 | METLIFE INVESTMENT MANAGEMENT, LLC | 297.1K +30.3K (+11.4%) | 392.1K +26.7K (+7.3%) | 0.04% +0.005 pp | 0.00% +0.000 pp | USD2.23 -40.8% | 33 qtrs — |
| 73 | MOODY NATIONAL BANK TRUST DIVISION | 295.4K -954.0 (-0.3%) | 390.0K -16.1K (-4.0%) | 0.04% 0.000 pp | 0.04% +0.003 pp | USD2.99 -55.9% | 11 qtrs — |
| 74 | JPMORGAN CHASE & CO | 264.5K -222.8K (-45.7%) | 349.1K -318.4K (-47.7%) | 0.04% -0.034 pp | 0.00% +0.000 pp | USD2.80 -52.9% | 45 qtrs — |
| 75 | XTX TOPCO LTD | 258.4K +92.9K (+56.1%) | 341.1K +114.3K (+50.4%) | 0.04% +0.014 pp | 0.01% -0.003 pp | USD1.46 -9.6% | 16 qtrs — |
| 76 | JANUS HENDERSON GROUP PLC | 239.4K +— (+0.0%) | 317.1K -12.0K (-3.6%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD4.29 -69.2% | 18 qtrs — |
| 77 | INTECH INVESTMENT MANAGEMENT LLC | 234.0K +— (+0.0%) | 308.9K -11.7K (-3.6%) | 0.04% +0.000 pp | 0.00% 0.000 pp | USD3.32 -60.2% | 6 qtrs — |
| 78 | NVEST FINANCIAL, LLC | 228.8K -84.9K (-27.1%) | 302.0K -127.8K (-29.7%) | 0.03% -0.013 pp | 0.13% -0.121 pp | USD2.71 -51.3% | 5 qtrs — |
| 79 | SCIENTECH RESEARCH LLC | 227.5K +227.5K (+100.0%) | 300.3K +300.3K (+100.0%) | 0.03% +0.034 pp | 0.19% +0.189 pp | USD1.32 +0.0% | 1 qtrs NEW |
| 80 | RUSSELL INVESTMENTS GROUP, LTD. | 225.0K -5.3K (-2.3%) | 297.1K -18.5K (-5.9%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD2.95 -55.3% | 17 qtrs — |
| 81 | GROUP ONE TRADING, L.P. | 205.7K -14.9K (-6.8%) | 271.5K -30.7K (-10.2%) | 0.03% -0.002 pp | 0.00% 0.000 pp | USD1.59 -17.0% | 4 qtrs — |
| 82 | CREATIVE PLANNING | 203.8K -144.7K (-41.5%) | 269.1K -208.5K (-43.7%) | 0.03% -0.022 pp | 0.00% 0.000 pp | USD1.84 -28.3% | 10 qtrs — |
| 83 | STATE OF WISCONSIN INVESTMENT BOARD | 202.5K -16.9K (-7.7%) | 267.3K -33.2K (-11.1%) | 0.03% -0.003 pp | 0.00% 0.000 pp | USD2.90 -54.5% | 15 qtrs — |
| 84 | CRESSET ASSET MANAGEMENT, LLC | 188.5K +5.7K (+3.1%) | 248.9K -1.6K (-0.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD3.04 -56.6% | 11 qtrs — |
| 85 | RAYMOND JAMES FINANCIAL INC | 183.4K -31.1K (-14.5%) | 242.0K -51.7K (-17.6%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD2.16 -38.9% | 5 qtrs — |
| 86 | QUADRATURE CAPITAL LTD | 178.5K -83.4K (-31.8%) | 235.6K -123.1K (-34.3%) | 0.03% -0.013 pp | 0.00% -0.002 pp | USD1.45 -9.0% | 4 qtrs — |
| 87 | NEW YORK STATE COMMON RETIREMENT FUND | 171.5K +— (+0.0%) | 226.3K -8.6K (-3.6%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD2.71 -51.3% | 43 qtrs — |
| 88 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 166.8K -13.6K (-7.5%) | 220.2K -27.0K (-10.9%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD3.44 -61.6% | 51 qtrs — |
| 89 | SG AMERICAS SECURITIES, LLC | 158.8K +45.5K (+40.1%) | 210.0K +55.0K (+35.5%) | 0.02% +0.007 pp | 0.00% 0.000 pp | USD1.36 -2.9% | 33 qtrs — |
| 90 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 153.4K +— (+0.0%) | 202.5K -7.7K (-3.6%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.13 -57.8% | 5 qtrs — |
| 91 | ENTRYPOINT CAPITAL, LLC | 151.9K +151.9K (+100.0%) | 200.5K +200.5K (+100.0%) | 0.02% +0.023 pp | 0.08% +0.078 pp | USD1.32 +0.0% | 1 qtrs NEW |
| 92 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 142.1K +— (+0.0%) | 187.6K -7.1K (-3.6%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD2.12 -37.7% | 51 qtrs — |
| 93 | CITIGROUP INC | 139.4K +63.1K (+82.7%) | 184.0K +79.4K (+76.0%) | 0.02% +0.009 pp | 0.00% +0.000 pp | USD2.44 -45.9% | 61 qtrs — |
| 94 | ARIZONA STATE RETIREMENT SYSTEM | 134.9K -5.9K (-4.2%) | 178.1K -14.9K (-7.7%) | 0.02% -0.001 pp | 0.00% 0.000 pp | USD2.43 -45.7% | 24 qtrs — |
| 95 | VIRTU FINANCIAL LLC | 129.3K +129.3K (+100.0%) | 171.0K +171.0K (+100.0%) | 0.02% +0.019 pp | 0.01% +0.007 pp | USD1.32 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
2.50M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,500,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-13 | Williams Timothy | Officer | A-Award | A | Stock Option (Right to Buy) | 2,500,000 | 1.73 | 4.33M | 2,500,000 | D | ↗ |
| 2026-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,243 | 1.49 | 7.8K | 199,707 | D | ↗ |
| 2026-03-25 | Chinoporos Constantine | Director | A-Award | A | Stock Option (Right to Buy) | 270,000 | 1.57 | 423.9K | 270,000 | D | ↗ |
| 2026-03-25 | Andrews Patricia S | Director | A-Award | A | Stock Option (Right to Buy) | 270,000 | 1.57 | 423.9K | 270,000 | D | ↗ |
| 2026-02-18 | ROBERTSON MICHELLE | Officer | M-Exempt | D | Restricted Stock Units | 27,500 | 0.00 | — | 82,500 | D | ↗ |
| 2026-02-17 | ROBERTSON MICHELLE | Officer | A-Award | A | Stock Option (Right to Buy) | 1,660,000 | 1.80 | 2.99M | 1,660,000 | D | ↗ |
| 2026-02-17 | Eid Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 2,220,000 | 1.80 | 4.00M | 2,220,000 | D | ↗ |
| 2025-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,918 | 1.32 | 7.8K | 194,464 | D | ↗ |
| 2025-10-20 | ElNawawi Ahmed | Officer | A-Award | A | Stock Option (right to buy) | 3,000,000 | 1.27 | 3.81M | 3,000,000 | D | ↗ |
| 2025-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,702 | 1.37 | 7.8K | 188,546 | D | ↗ |
| 2025-08-07 | Semerjian Harout | Director / Officer | A-Award | A | Stock Option (right to buy) | 7,000,000 | 1.30 | 9.10M | 7,000,000 | D | ↗ |
| 2025-06-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,540 | 1.41 | 7.8K | 182,844 | D | ↗ |
| 2025-05-21 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | McDonald John F | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | Bir Dawn Carter | Director / Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-21 | Aggarwal Gaurav | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 1.34 | 241.2K | 180,000 | D | ↗ |
| 2025-05-09 | LAWLIS V BRYAN | Director | P-Purchase | A | Common Stock | 13,300 | 1.18 | 15.7K | 13,300 | D | ↗ |
| 2025-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,913 | 1.59 | 7.8K | 177,304 | D | ↗ |
| 2025-02-27 | Ziegler James | Officer | P-Purchase | A | Common Stock | 100,000 | 1.60 | 160.0K | 100,000 | D | ↗ |
| 2025-02-27 | Samuels Scott Alan | Officer | P-Purchase | A | Common Stock | 15,000 | 1.61 | 24.2K | 26,682 | D | ↗ |
| 2025-02-27 | SCARLETT JOHN A | Director / Officer | P-Purchase | A | Common Stock | 12,500 | 1.77 | 22.1K | 12,500 | D | ↗ |
| 2025-02-18 | Ziegler James | Officer | A-Award | A | Restricted Stock Units | 89,000 | 0.00 | — | 89,000 | D | ↗ |
| 2025-02-18 | Samuels Scott Alan | Officer | A-Award | A | Restricted Stock Units | 104,000 | 0.00 | — | 104,000 | D | ↗ |
| 2025-02-18 | SCARLETT JOHN A | Director / Officer | A-Award | A | Restricted Stock Units | 410,000 | 0.00 | — | 410,000 | D | ↗ |
| 2025-02-18 | ROBERTSON MICHELLE | Officer | A-Award | A | Restricted Stock Units | 110,000 | 0.00 | — | 110,000 | D | ↗ |
| 2025-02-18 | GRETHLEIN ANDREW J | Officer | A-Award | A | Restricted Stock Units | 140,000 | 0.00 | — | 140,000 | D | ↗ |
| 2024-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 2,206 | 3.54 | 7.8K | 172,391 | D | ↗ |
| 2024-11-11 | Eid Joseph | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 1,767 | 4.54 | 8.0K | 170,185 | D | ↗ |
| 2024-09-09 | Ziegler James | Officer | A-Award | D | Stock Option (right to buy) | 1,600,000 | 4.41 | 7.06M | 1,600,000 | — | ↗ |
| 2024-07-08 | GRETHLEIN ANDREW J | Officer | M-Exempt | D | Stock Option (right to buy) | 452,804 | 1.72 | 778.8K | 0 | — | ↗ |
| 2024-06-28 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 1,916 | 4.24 | 8.1K | 168,418 | D | ↗ |
| 2024-06-10 | Kapur Anil | Officer | M-Exempt | A | Common Stock | 421,875 | 1.06 | 447.2K | 421,875 | — | ↗ |
| 2024-06-10 | Feller Faye | Officer | M-Exempt | A | Common Stock | 20,000 | 1.06 | 21.2K | 20,000 | — | ↗ |
| 2024-06-06 | Samuels Scott Alan | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 3.21 | 802.5K | 250,000 | — | ↗ |
| 2024-06-06 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,000,000 | 1.72 | 1.72M | 1,000,000 | — | ↗ |
| 2024-06-06 | ROBERTSON MICHELLE | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 2.17 | 542.5K | 250,000 | — | ↗ |
| 2024-06-06 | Kapur Anil | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 1.43 | 357.5K | 250,000 | — | ↗ |
| 2024-06-06 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 452,804 | 1.72 | 778.8K | 452,804 | — | ↗ |
| 2024-06-06 | Feller Faye | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.93 | 386.0K | 200,000 | — | ↗ |
| 2024-06-04 | SCARLETT JOHN A | Director / Officer | S-Sale | D | Common Stock | 600,000 | 4.00 | 2.40M | 600,000 | — | ↗ |
| 2024-05-15 | LAWLIS V BRYAN | Director | S-Sale | D | Common Stock | 35,000 | 3.75 | 131.3K | 0 | — | ↗ |
| 2024-05-09 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | McDonald John F | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-05-09 | Aggarwal Gaurav | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 3.88 | 698.4K | 180,000 | — | ↗ |
| 2024-03-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 2,462 | 3.30 | 8.1K | 166,502 | D | ↗ |
| 2024-02-14 | Samuels Scott Alan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 850,000 | 2.10 | 1.79M | 850,000 | — | ↗ |
| 2024-02-14 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 3,000,000 | 2.10 | 6.30M | 3,000,000 | — | ↗ |
| 2024-02-14 | ROBERTSON MICHELLE | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 850,000 | 2.10 | 1.79M | 850,000 | — | ↗ |
| 2024-02-14 | Kapur Anil | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 750,000 | 2.10 | 1.58M | 750,000 | — | ↗ |
| 2024-02-14 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,200,000 | 2.10 | 2.52M | 1,200,000 | — | ↗ |
| 2024-02-14 | Feller Faye | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 750,000 | 2.10 | 1.58M | 750,000 | — | ↗ |
| 2023-12-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 3,406 | 0.00 | — | 164,040 | — | ↗ |
| 2023-12-29 | Molineaux Susan | Director | A-Award | A | Common Stock | 6,220 | 0.00 | — | 130,527 | — | ↗ |
| 2023-12-29 | Aggarwal Gaurav | Director | A-Award | A | Common Stock | 1,970 | 0.00 | — | 1,970 | — | ↗ |
| 2023-11-26 | Aggarwal Gaurav | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 1.97 | 394.0K | 200,000 | — | ↗ |
| 2023-09-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 3,390 | 0.00 | — | 160,634 | — | ↗ |
| 2023-09-29 | Molineaux Susan | Director | A-Award | A | Common Stock | 6,191 | 0.00 | — | 124,307 | — | ↗ |
| 2023-09-25 | ROBERTSON MICHELLE | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-24 | O'Farrell Elizabeth G. | Director | P-Purchase | A | Common Stock | 6,579 | 2.28 | 15.0K | 26,220 | — | ↗ |
| 2023-08-15 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (Right to buy) | 500,000 | 1.72 | 860.0K | 500,000 | — | ↗ |
| 2023-08-15 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 221,544 | 1.72 | 381.1K | 221,544 | — | ↗ |
| 2023-08-15 | Feller Faye | Officer | A-Award | A | Employee Stock Option (right to buy) | 20,000 | 1.06 | 21.2K | 20,000 | — | ↗ |
| 2023-08-15 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 1.72 | 430.0K | 250,000 | — | ↗ |
| 2023-08-01 | Samuels Scott Alan | Officer | A-Award | A | Employee Stock Option (right to buy) | 1,350,000 | 3.21 | 4.33M | 1,350,000 | — | ↗ |
| 2023-06-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 2,239 | 0.00 | — | 157,244 | — | ↗ |
| 2023-06-30 | Molineaux Susan | Director | A-Award | A | Common Stock | 4,088 | 0.00 | — | 118,116 | — | ↗ |
| 2023-06-30 | Kapur Anil | Officer | A-Award | A | Common Stock | 7,567 | 2.04 | 15.4K | 60,783 | — | ↗ |
| 2023-05-31 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-31 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-31 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-31 | McDonald John F | Director | A-Award | A | Stock Options (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-31 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-31 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2023-05-11 | LAWLIS V BRYAN | Director | M-Exempt | A | Common Stock | 35,000 | 1.10 | 38.5K | 35,000 | — | ↗ |
| 2023-05-01 | Molineaux Susan | Director | S-Sale | D | Common Stock | 35,000 | 2.48 | 86.8K | 0 | — | ↗ |
| 2023-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 3,312 | 0.00 | — | 155,005 | — | ↗ |
| 2023-03-31 | Molineaux Susan | Director | A-Award | A | Common Stock | 6,048 | 0.00 | — | 114,028 | — | ↗ |
| 2023-02-22 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (Right to buy) | 1,750,000 | 2.83 | 4.95M | 1,750,000 | — | ↗ |
| 2023-02-22 | Kapur Anil | Officer | A-Award | A | Employee Stock Option (right to buy) | 625,000 | 2.83 | 1.77M | 625,000 | — | ↗ |
| 2023-02-22 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 780,000 | 2.83 | 2.21M | 780,000 | — | ↗ |
| 2023-02-22 | Feller Faye | Officer | A-Award | A | Employee Stock Option (right to buy) | 540,000 | 2.83 | 1.53M | 540,000 | — | ↗ |
| 2023-02-22 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 575,000 | 2.83 | 1.63M | 575,000 | — | ↗ |
| 2023-02-10 | SCARLETT JOHN A | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 446,668 | 1.50 | 670.0K | 0 | — | ↗ |
| 2023-02-09 | SCARLETT JOHN A | Director / Officer | S-Sale | D | Common Stock | 446,666 | 3.03 | 1.35M | 0 | — | ↗ |
| 2023-02-09 | GRETHLEIN ANDREW J | Officer | M-Exempt | A | Common Stock | 150,000 | 1.51 | 226.5K | 384,719 | — | ↗ |
| 2023-02-08 | SCARLETT JOHN A | Director / Officer | S-Sale | D | Common Stock | 446,666 | 3.08 | 1.38M | 0 | — | ↗ |
| 2023-02-08 | Bloom Olivia Kyusuk | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400,000 | 1.51 | 604.0K | 0 | — | ↗ |
| 2023-01-13 | EASTHAM KARIN | Director | M-Exempt | A | Common Stock | 35,000 | 1.10 | 38.5K | 109,047 | — | ↗ |
| 2022-12-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 2,970 | 0.00 | — | 151,693 | — | ↗ |
| 2022-12-30 | Kapur Anil | Officer | A-Award | A | Common Stock | 6,021 | 1.11 | 6.7K | 53,216 | — | ↗ |
| 2022-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 3,071 | 0.00 | — | 148,723 | — | ↗ |
| 2022-09-07 | McDonald John F | Director | A-Award | A | Stock Options (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-07-08 | Feller Faye | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2022-06-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,637 | 0.00 | — | 145,652 | — | ↗ |
| 2022-06-30 | Kapur Anil | Officer | A-Award | A | Common Stock | 13,062 | 1.11 | 14.5K | 47,195 | — | ↗ |
| 2022-05-10 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-05-10 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-05-10 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-05-10 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 1.48 | 185.0K | 125,000 | — | ↗ |
| 2022-05-10 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-05-10 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-04-20 | EASTHAM KARIN | Director | M-Exempt | D | Stock Option (right to buy) | 35,000 | 1.41 | 49.4K | 0 | — | ↗ |
| 2022-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,284 | 0.00 | — | 141,015 | — | ↗ |
| 2022-02-16 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (Right to buy) | 2,100,000 | 1.06 | 2.23M | 2,100,000 | — | ↗ |
| 2022-02-16 | Rizo Aleksandra | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 1.06 | 795.0K | 750,000 | — | ↗ |
| 2022-02-16 | ROSENFIELD STEPHEN | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 1.06 | 795.0K | 750,000 | — | ↗ |
| 2022-02-16 | Kapur Anil | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 1.06 | 795.0K | 750,000 | — | ↗ |
| 2022-02-16 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 1.06 | 795.0K | 750,000 | — | ↗ |
| 2022-02-16 | Feller Faye | Officer | — | D | Stock Options (right to buy) | 200,000 | 1.06 | 212.0K | 0 | — | ↗ |
| 2022-02-16 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 1.06 | 795.0K | 750,000 | — | ↗ |
| 2021-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,891 | 0.00 | — | 135,731 | — | ↗ |
| 2021-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,246 | 0.00 | — | 129,840 | — | ↗ |
| 2021-06-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,097 | 0.00 | — | 124,594 | — | ↗ |
| 2021-05-11 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-05-11 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-05-11 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-05-11 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-05-11 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-05-11 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2021-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,549 | 0.00 | — | 119,497 | — | ↗ |
| 2021-02-02 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (Right to buy) | 600,000 | 2.06 | 1.23M | 600,000 | — | ↗ |
| 2021-02-02 | Rizo Aleksandra | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2021-02-02 | ROSENFIELD STEPHEN | Officer | A-Award | A | Employee Stock Option (Right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2021-02-02 | Kapur Anil | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2021-02-02 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2021-02-02 | Feller Faye | Officer | — | D | Stock Options (right to buy) | 155,400 | 2.06 | 319.3K | 0 | — | ↗ |
| 2021-02-02 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2021-02-02 | BEHRS MELISSA KELLY | Officer | A-Award | A | Employee Stock Option (Right to buy) | 300,000 | 2.06 | 616.5K | 300,000 | — | ↗ |
| 2020-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,520 | 0.00 | — | 114,948 | — | ↗ |
| 2020-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,130 | 0.00 | — | 110,428 | — | ↗ |
| 2020-08-21 | O'Farrell Elizabeth G. | Director | P-Purchase | A | Common Stock | 17,441 | 1.73 | 30.2K | 19,641 | — | ↗ |
| 2020-06-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 3,297 | 0.00 | — | 106,298 | — | ↗ |
| 2020-06-05 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-06-05 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-06-05 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-06-05 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-06-05 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-06-05 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 83,000 | 1.54 | 127.8K | 83,000 | — | ↗ |
| 2020-03-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 6,039 | 0.00 | — | 103,001 | — | ↗ |
| 2020-02-12 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 582,750 | 1.30 | 754.7K | 582,750 | — | ↗ |
| 2020-02-12 | Rizo Aleksandra | Officer | A-Award | A | Employee Stock Option (right to buy) | 291,375 | 1.30 | 377.3K | 291,375 | — | ↗ |
| 2020-02-12 | ROSENFIELD STEPHEN | Officer | A-Award | A | Employee Stock Option (right to buy) | 291,375 | 1.30 | 377.3K | 291,375 | — | ↗ |
| 2020-02-12 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 291,375 | 1.30 | 377.3K | 291,375 | — | ↗ |
| 2020-02-12 | Feller Faye | Officer | — | D | Stock Options (right to buy) | 155,400 | 1.30 | 201.2K | 0 | — | ↗ |
| 2020-02-12 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 291,375 | 1.30 | 377.3K | 291,375 | — | ↗ |
| 2020-02-12 | BEHRS MELISSA KELLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 291,375 | 1.30 | 377.3K | 291,375 | — | ↗ |
| 2020-01-10 | O'Farrell Elizabeth G. | Director | P-Purchase | A | Common Stock | 2,200 | 1.34 | 2.9K | 2,200 | — | ↗ |
| 2019-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,284 | 0.00 | — | 96,962 | — | ↗ |
| 2019-12-02 | Kapur Anil | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-30 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,404 | 0.00 | — | 91,678 | — | ↗ |
| 2019-06-28 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 5,097 | 0.00 | — | 86,274 | — | ↗ |
| 2019-06-06 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-06-06 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-06-06 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-06-06 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-06-06 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-06-06 | Bir Dawn Carter | Director | A-Award | A | Srock Option (right to buy) | 70,000 | 1.38 | 96.6K | 70,000 | — | ↗ |
| 2019-04-17 | Feller Faye | Officer | — | D | Stock Options (right to buy) | 80,000 | 1.74 | 139.2K | 0 | — | ↗ |
| 2019-04-09 | BEHRS MELISSA KELLY | Officer | S-Sale | D | Common Stock | 120,635 | 2.00 | 241.3K | 0 | — | ↗ |
| 2019-03-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,329 | 0.00 | — | 81,177 | — | ↗ |
| 2019-03-29 | BRADBURY DANIEL | Director | A-Award | A | Commmon Stock | 9,036 | 0.00 | — | 51,323 | — | ↗ |
| 2019-03-26 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 1.68 | 201.6K | 120,000 | — | ↗ |
| 2019-03-26 | Bir Dawn Carter | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 1.68 | 201.6K | 120,000 | — | ↗ |
| 2019-01-30 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,050,000 | 1.03 | 1.08M | 1,050,000 | — | ↗ |
| 2019-01-30 | Rizo Aleksandra | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-01-30 | ROSENFIELD STEPHEN | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.03 | 309.0K | 300,000 | — | ↗ |
| 2019-01-30 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.03 | 309.0K | 300,000 | — | ↗ |
| 2019-01-30 | Bloom Olivia Kyusuk | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.03 | 309.0K | 300,000 | — | ↗ |
| 2019-01-30 | BEHRS MELISSA KELLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.03 | 309.0K | 300,000 | — | ↗ |
| 2018-12-31 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 7,188 | 0.00 | — | 76,848 | — | ↗ |
| 2018-12-31 | Molineaux Susan | Director | A-Award | A | Common Stock | 13,125 | 0.00 | — | 107,980 | — | ↗ |
| 2018-12-31 | BRADBURY DANIEL | Director | A-Award | A | Common Stock | 15,000 | 0.00 | — | 42,287 | — | ↗ |
| 2018-09-28 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 4,084 | 0.00 | — | 69,660 | — | ↗ |
| 2018-09-28 | Molineaux Susan | Director | A-Award | A | Common Stock | 7,457 | 0.00 | — | 94,855 | — | ↗ |
| 2018-09-28 | BRADBURY DANIEL | Director | A-Award | A | Common Stock | 8,523 | 0.00 | — | 27,287 | — | ↗ |
| 2018-09-13 | Spiegel Robert J. | Director | S-Sale | D | Common Stock | 35,000 | 6.85 | 239.8K | 65,576 | — | ↗ |
| 2018-08-24 | ROSENFIELD STEPHEN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 200,000 | 1.41 | 282.0K | 0 | — | ↗ |
| 2018-06-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 2,095 | 0.00 | — | 65,576 | — | ↗ |
| 2018-06-29 | Molineaux Susan | Director | A-Award | A | Common Stock | 3,827 | 0.00 | — | 87,398 | — | ↗ |
| 2018-06-29 | BRADBURY DANIEL | Director | A-Award | A | Common Stock | 4,373 | 0.00 | — | 18,764 | — | ↗ |
| 2018-05-15 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-05-15 | Molineaux Susan | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-05-15 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-05-15 | Huh Hoyoung | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-05-15 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-05-15 | BRADBURY DANIEL | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 3.43 | 240.1K | 70,000 | — | ↗ |
| 2018-03-29 | Spiegel Robert J. | Director | A-Award | A | Common Stock | 1,691 | 0.00 | — | 63,481 | — | ↗ |
| 2018-03-29 | Molineaux Susan | Director | A-Award | A | Common Stock | 3,088 | 0.00 | — | 83,571 | — | ↗ |
| 2018-03-29 | BRADBURY DANIEL | Director | A-Award | A | Common Stock | 3,529 | 0.00 | — | 14,391 | — | ↗ |
| 2018-01-31 | SCARLETT JOHN A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,050,000 | 2.45 | 2.57M | 1,050,000 | — | ↗ |
| 2018-01-31 | ROSENFIELD STEPHEN | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.45 | 735.0K | 300,000 | — | ↗ |
| 2018-01-31 | GRETHLEIN ANDREW J | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.45 | 735.0K | 300,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-232.0K
Shares Outstanding
640.90M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Harout Semerjian President and Chief Executive Officer (as of August 7, 2025) | 321.5K | — | — | 9.70M | 203.0K | 1.8K | 10.22M | 94.85% | ↗ |
| 2 | 2025 | John A. Scarlett, M.D. Former Chairman of the Board, President and Chief Executive Officer | 309.8K | — | 1.08M | 4.31M | — | 1.73M | 7.42M | 72.57% | ↗ |
| 3 | 2025 | Andrew J. Grethlein, Ph.D. Former Executive Vice President, Chief Operating Officer | 563.3K | — | 368.2K | 1.47M | — | 910.7K | 3.32M | 55.56% | ↗ |
| 4 | 2025 | Ahmed ElNawawi Executive Vice President, Chief Commercial Officer (as of October 20, 2025) | 107.7K | 200.0K | — | 2.57M | — | 242.00 | 2.88M | 89.31% | ↗ |
| 5 | 2025 | James Ziegler Former Executive Vice President, Chief Commercial Officer (as of September 9, 2024) | 470.0K | — | 234.1K | 927.5K | — | 761.1K | 2.39M | 48.55% | ↗ |
| 6 | 2025 | Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary | 559.8K | — | 289.3K | 1.15M | 239.3K | 11.5K | 2.25M | 63.98% | ↗ |
| 7 | 2025 | Joseph Eid, M.D. Executive Vice President, Research & Development, Chief Medical Officer (as of November 11, 2024) | 650.0K | — | — | — | 339.6K | 11.5K | 1.00M | 0.00% | ↗ |
| 8 | 2025 | Dawn C. Bir Former Interim President and Chief Executive Officer (as of March 17, 2025) | 318.2K | — | — | 163.7K | — | 40.3K | 522.1K | 31.35% | ↗ |
| 9 | 2024 | Joseph Eid, M.D. Executive Vice President, Research & Development, Chief Medical Officer (as of November 11, 2024) | 93.8K | 200.0K | — | 6.90M | — | 10.3K | 7.76M | 88.92% | ↗ |
| 10 | 2024 | Joseph Eid, M.D. Executive Vice President, Research & Development (as of November 11, 2024) | 93.8K | 200.0K | — | 6.90M | — | 10.3K | 7.76M | 88.92% | ↗ |
| 11 | 2024 | Andrew J. Grethlein, Ph.D. Former Executive Vice President, Chief Operating Officer | 93.8K | 200.0K | — | 6.90M | — | 10.3K | 7.21M | 95.78% | ↗ |
| 12 | 2024 | John A. Scarlett, M.D. Former Chairman of the Board, President and Chief Executive Officer | 810.6K | — | — | 4.59M | 658.6K | 64.8K | 6.13M | 74.96% | ↗ |
| 13 | 2024 | James Ziegler Executive Vice President, Chief Commercial Officer (as of September 9, 2024) | 163.2K | — | — | 5.15M | 88.3K | 1.0K | 5.77M | 89.35% | ↗ |
| 14 | 2024 | James Ziegler Former Executive Vice President, Chief Commercial Officer (as of September 9, 2024) | 163.2K | — | — | 5.15M | 88.3K | 1.0K | 5.77M | 89.35% | ↗ |
| 15 | 2024 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 6.0K | — | — | 1.84M | 364.5K | 13.0K | 2.81M | 65.26% | ↗ |
| 16 | 2024 | Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary | 540.8K | — | — | 1.30M | 292.0K | 13.6K | 2.15M | 60.58% | ↗ |
| 17 | 2024 | Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer and Treasurer (as of September 25, 2023) | 540.8K | — | — | 1.30M | 292.0K | 13.6K | 2.15M | 60.58% | ↗ |
| 18 | 2023 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 787.0K | 17.9K | — | 3.56M | 493.7K | 62.5K | 4.92M | 72.36% | ↗ |
| 19 | 2023 | John A. Scarlett, M.D. Former Chairman of the Board, President and Chief Executive Officer | 787.0K | 17.9K | — | 3.56M | 493.7K | 62.5K | 4.92M | 72.36% | ↗ |
| 20 | 2023 | Scott A. Samuels Executive Vice President, Chief Legal Officer and Secretary (as of August 1, 2023) | 218.8K | 151.8K | — | 3.12M | 103.2K | 11.6K | 3.61M | 86.55% | ↗ |
| 21 | 2023 | Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer and Treasurer (as of September 25, 2023) | 141.3K | 126.2K | — | 2.13M | 67.0K | 6.4K | 2.47M | 86.19% | ↗ |
| 22 | 2023 | Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary | 141.3K | 126.2K | — | 2.13M | 67.0K | 6.4K | 2.47M | 86.19% | ↗ |
| 23 | 2023 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 525.0K | 5.0K | — | 1.59M | 281.1K | 15.9K | 2.42M | 65.76% | ↗ |
| 24 | 2023 | Andrew J. Grethlein, Ph.D. Former Executive Vice President, Chief Operating Officer | 525.0K | 5.0K | — | 1.59M | 281.1K | 15.9K | 2.42M | 65.76% | ↗ |
| 25 | 2022 | John A. Scarlett, M.D. Former Chairman of the Board, President and Chief Executive Officer | 761.3K | — | — | 1.47M | 671.0K | 96.1K | 3.00M | 49.00% | ↗ |
| 26 | 2022 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 761.3K | — | — | 1.47M | 671.0K | 96.1K | 3.00M | 49.00% | ↗ |
| 27 | 2022 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 507.5K | — | — | 524.6K | 302.5K | 37.2K | 1.37M | 38.24% | ↗ |
| 28 | 2022 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 507.5K | — | — | 524.6K | 302.5K | 16.0K | 1.35M | 38.84% | ↗ |
| 29 | 2021 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 735.6K | — | — | 796.7K | 441.3K | 83.4K | 2.06M | 38.73% | ↗ |
| 30 | 2021 | Aleksandra Rizo, M.D., Ph.D. Executive Vice President, Chief Medical Officer | 506.4K | 95.0K | — | 398.4K | 241.5K | 23.9K | 1.27M | 31.49% | ↗ |
| 31 | 2021 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 490.4K | — | — | 398.4K | 240.5K | 36.4K | 1.17M | 34.18% | ↗ |
| 32 | 2021 | Melissa A. Kelly Behrs Executive Vice President, Business Operations and Chief Alliance Officer | 453.1K | — | — | 398.4K | 213.1K | 87.0K | 1.15M | 34.59% | ↗ |
| 33 | 2021 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 490.4K | — | — | 398.4K | 237.2K | 15.7K | 1.14M | 34.89% | ↗ |
| 34 | 2021 | Anil Kapur Executive Vice President, Corporate Strategy and Chief Commercial Officer | 432.6K | — | — | 398.4K | 206.4K | 15.9K | 1.05M | 37.82% | ↗ |
| 35 | 2020 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 714.2K | — | — | 485.3K | 599.9K | 76.9K | 1.88M | 25.87% | ↗ |
| 36 | 2020 | Aleksandra Rizo, M.D., Ph.D. Executive Vice President, Chief Medical Officer | 491.6K | 100.0K | — | 242.7K | 278.8K | 21.9K | 1.13M | 21.38% | ↗ |
| 37 | 2020 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 476.1K | — | — | 242.7K | 270.0K | 45.5K | 1.03M | 23.46% | ↗ |
| 38 | 2020 | Melissa A. Kelly Behrs Executive Vice President, Business Operations and Chief Alliance Officer | 439.9K | — | — | 242.7K | 243.5K | 81.5K | 1.01M | 24.09% | ↗ |
| 39 | 2020 | Melissa A. Kelly Behrs Executive Vice President, Chief Business Officer | 439.9K | — | — | 242.7K | 243.5K | 81.5K | 1.01M | 24.09% | ↗ |
| 40 | 2020 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 476.1K | — | — | 242.7K | 270.0K | 15.5K | 1.00M | 24.16% | ↗ |
| 41 | 2020 | Anil Kapur Executive Vice President, Corporate Strategy and Chief Commercial Officer | 420.0K | — | — | — | 238.1K | 15.5K | 673.6K | 0.00% | ↗ |
| 42 | 2019 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 690.0K | 41.4K | — | 788.6K | 331.2K | 90.0K | 1.94M | 40.62% | ↗ |
| 43 | 2019 | Aleksandra Rizo, M.D., Ph.D. Executive Vice President, Chief Medical Officer | 475.0K | 284.8K | — | 563.3K | 188.3K | 20.1K | 1.53M | 36.78% | ↗ |
| 44 | 2019 | Anil Kapur Executive Vice President, Corporate Strategy and Chief Commercial Officer | 420.0K | 150.0K | — | 652.3K | — | — | 1.22M | 53.37% | ↗ |
| 45 | 2019 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 460.0K | 10.4K | — | 225.3K | 192.5K | 42.8K | 931.0K | 24.20% | ↗ |
| 46 | 2019 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 460.0K | 10.4K | — | 225.3K | 201.8K | 15.0K | 912.5K | 24.69% | ↗ |
| 47 | 2019 | Melissa A. Kelly Behrs Executive Vice President, Business Operations and Chief Alliance Officer | 425.0K | 9.6K | — | 225.3K | 177.9K | 60.9K | 898.7K | 25.07% | ↗ |
| 48 | 2019 | Melissa A. Kelly Behrs Executive Vice President, Chief Business Officer | 425.0K | 9.6K | — | 225.3K | 177.9K | 60.9K | 898.7K | 25.07% | ↗ |
| 49 | 2018 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 667.0K | — | — | 1.74M | 280.1K | 86.8K | 2.77M | 62.71% | ↗ |
| 50 | 2018 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 445.0K | — | — | 579.5K | 185.2K | 14.5K | 1.22M | 47.34% | ↗ |
| 51 | 2018 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 430.0K | — | — | 496.7K | 181.9K | 41.6K | 1.15M | 43.19% | ↗ |
| 52 | 2018 | Melissa A. Kelly Behrs Executive Vice President, Chief Business Officer | 400.0K | — | — | 496.7K | 169.2K | 41.1K | 1.11M | 44.87% | ↗ |
| 53 | 2018 | Stephen N. Rosenfield, J.D. Executive Vice President, Chief Legal Officer and Corporate Secretary | 356.0K | — | — | 496.7K | 148.2K | 13.9K | 1.01M | 48.95% | ↗ |
| 54 | 2017 | John A. Scarlett, M.D. President and Chief Executive Officer | 644.0K | — | — | 1.63M | 386.4K | 63.0K | 2.72M | 59.79% | ↗ |
| 55 | 2017 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 644.0K | — | — | 1.63M | 386.4K | 63.0K | 2.72M | 59.79% | ↗ |
| 56 | 2017 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 416.2K | — | — | 464.6K | 204.1K | 38.8K | 1.12M | 41.34% | ↗ |
| 57 | 2017 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 416.2K | — | — | 464.6K | 204.1K | 38.8K | 1.12M | 41.34% | ↗ |
| 58 | 2017 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 410.0K | — | — | 464.6K | 201.1K | 28.3K | 1.10M | 42.08% | ↗ |
| 59 | 2017 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio & Alliance Management | 386.5K | — | — | 464.6K | 189.6K | 37.9K | 1.08M | 43.07% | ↗ |
| 60 | 2017 | Melissa A. Kelly Behrs Executive Vice President, Chief Business Officer | 386.5K | — | — | 464.6K | 189.6K | 37.9K | 1.08M | 43.07% | ↗ |
| 61 | 2017 | Stephen N. Rosenfield, J.D. Executive Vice President, Chief Legal Officer and Corporate Secretary | 342.6K | — | — | 464.6K | 165.8K | 13.9K | 986.9K | 47.07% | ↗ |
| 62 | 2017 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 342.6K | — | — | 464.6K | 165.8K | 13.9K | 986.9K | 47.07% | ↗ |
| 63 | 2016 | John A. Scarlett, M.D. Chairman of the Board, President and Chief Executive Officer | 622.2K | — | — | 1.09M | 373.3K | 78.4K | 2.16M | 50.30% | ↗ |
| 64 | 2016 | John A. Scarlett, M.D. President and Chief Executive Officer | 622.2K | — | — | 1.09M | 373.3K | 78.4K | 2.16M | 50.30% | ↗ |
| 65 | 2016 | Andrew J. Grethlein, Ph.D. Executive Vice President, Chief Operating Officer | 402.1K | — | — | 380.4K | 186.4K | 38.7K | 1.01M | 37.75% | ↗ |
| 66 | 2016 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 402.1K | — | — | 380.4K | 186.4K | 38.7K | 1.01M | 37.75% | ↗ |
| 67 | 2016 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 387.2K | — | — | 380.4K | 179.5K | 28.5K | 975.7K | 38.99% | ↗ |
| 68 | 2016 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio & Alliance Management | 373.4K | — | — | 380.4K | 173.1K | 41.0K | 967.9K | 39.30% | ↗ |
| 69 | 2016 | Melissa A. Kelly Behrs Executive Vice President, Chief Business Officer | 373.4K | — | — | 380.4K | 173.1K | 41.0K | 967.9K | 39.30% | ↗ |
| 70 | 2016 | Stephen N. Rosenfield, J.D. Executive Vice President, Chief Legal Officer and Corporate Secretary | 331.0K | — | — | 380.4K | 153.4K | 13.9K | 878.7K | 43.29% | ↗ |
| 71 | 2016 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 331.0K | — | — | 380.4K | 153.4K | 13.9K | 878.7K | 43.29% | ↗ |
| 72 | 2015 | John A. Scarlett, M.D. President and Chief Executive Officer | 604.1K | — | — | 1.86M | 362.5K | 61.8K | 2.89M | 64.39% | ↗ |
| 73 | 2015 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 390.4K | — | — | 650.8K | 180.9K | 36.3K | 1.26M | 51.71% | ↗ |
| 74 | 2015 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio & Alliance Management | 362.6K | — | — | 650.8K | 172.9K | 35.3K | 1.22M | 53.28% | ↗ |
| 75 | 2015 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 376.0K | — | — | 650.8K | 174.3K | 12.5K | 1.21M | 53.63% | ↗ |
| 76 | 2015 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 321.4K | — | — | 650.8K | 149.0K | 13.9K | 1.13M | 57.34% | ↗ |
| 77 | 2014 | John A. Scarlett, M.D. President and Chief Executive Officer | 586.5K | 70.4K | — | 5.00M | 351.9K | 60.8K | 6.07M | 82.38% | ↗ |
| 78 | 2014 | John A. Scarlett, M.D. President and Chief Executive Officer | 586.5K | 70.4K | — | 5.00M | 351.9K | 60.8K | 6.07M | 82.38% | ↗ |
| 79 | 2014 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 379.0K | 17.1K | — | 1.47M | 180.8K | 34.4K | 2.08M | 70.61% | ↗ |
| 80 | 2014 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 379.0K | 17.1K | — | 1.47M | 180.8K | 34.4K | 2.08M | 70.61% | ↗ |
| 81 | 2014 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio Alliance Management | 352.0K | 15.8K | — | 1.47M | 172.7K | 33.5K | 2.04M | 71.90% | ↗ |
| 82 | 2014 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio & Alliance Management | 352.0K | 15.8K | — | 1.47M | 172.7K | 33.5K | 2.04M | 71.90% | ↗ |
| 83 | 2014 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 365.0K | 16.4K | — | 1.47M | 174.1K | 12.1K | 2.04M | 72.12% | ↗ |
| 84 | 2014 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 365.0K | 16.4K | — | 1.47M | 174.1K | 12.1K | 2.04M | 72.12% | ↗ |
| 85 | 2014 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 312.0K | 14.0K | — | 1.47M | 148.8K | 13.3K | 1.96M | 75.05% | ↗ |
| 86 | 2014 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 312.0K | 14.0K | — | 1.47M | 148.8K | 13.3K | 1.96M | 75.05% | ↗ |
| 87 | 2013 | John A. Scarlett, M.D. President and Chief Executive Officer | 569.3K | — | — | 1.31M | 341.6K | 59.3K | 2.28M | 57.42% | ↗ |
| 88 | 2013 | John A. Scarlett, M.D. President and Chief Executive Officer | 569.3K | — | — | 1.31M | 341.6K | 59.3K | 2.28M | 57.42% | ↗ |
| 89 | 2013 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 330.0K | — | — | 462.9K | 136.0K | 28.3K | 957.2K | 48.36% | ↗ |
| 90 | 2013 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 330.0K | — | — | 462.9K | 136.0K | 28.3K | 957.2K | 48.36% | ↗ |
| 91 | 2013 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio Alliance Management | 341.6K | — | — | 417.5K | 148.9K | 38.3K | 946.3K | 44.12% | ↗ |
| 92 | 2013 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio & Alliance Management | 341.6K | — | — | 417.5K | 148.9K | 38.3K | 946.3K | 44.12% | ↗ |
| 93 | 2013 | Melissa A. Kelly Behrs Executive Vice President, Portfolio and Alliance Management | 341.6K | — | — | — | 148.9K | 38.3K | 946.3K | 0.00% | ↗ |
| 94 | 2013 | Stephen N. Rosenfield, J.D. Executive Vice President, General | 302.2K | — | — | — | 146.2K | 19.0K | 883.4K | 0.00% | ↗ |
| 95 | 2013 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 302.2K | — | — | 415.9K | 146.2K | 19.0K | 883.4K | 47.08% | ↗ |
| 96 | 2013 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 302.2K | — | — | 415.9K | 146.2K | 19.0K | 883.4K | 47.08% | ↗ |
| 97 | 2013 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 367.4K | — | — | 294.6K | 170.3K | 34.2K | 866.6K | 34.00% | ↗ |
| 98 | 2013 | Andrew J. Grethlein, Ph.D. Executive Vice President, | 367.4K | — | — | — | 170.3K | 34.2K | 866.6K | 0.00% | ↗ |
| 99 | 2013 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 367.4K | — | — | 294.6K | 170.3K | 34.2K | 866.6K | 34.00% | ↗ |
| 100 | 2012 | Graham K. Cooper | 362.1K | — | — | 650.9K | — | 550.1K | 1.56M | 41.64% | ↗ |
| 101 | 2012 | John A. Scarlett, M.D. President and Chief Executive Officer | 550.0K | 39.6K | — | — | 290.4K | 54.8K | 1.34M | 0.00% | ↗ |
| 102 | 2012 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 255.5K | — | — | 685.5K | 133.4K | 112.9K | 1.19M | 57.74% | ↗ |
| 103 | 2012 | Stephen N. Rosenfield, J.D. Executive Vice President, General Counsel and Corporate Secretary | 255.5K | — | — | 685.5K | 133.4K | 112.9K | 1.19M | 57.74% | ↗ |
| 104 | 2012 | Stephen N. Rosenfield, J.D. Executive Vice President, General | 255.5K | — | — | — | 133.4K | 112.9K | 1.19M | 0.00% | ↗ |
| 105 | 2012 | F.R.C.Path. Executive Vice President, RD and Chief Medical Officer | 415.0K | — | — | 365.4K | 181.1K | 42.0K | 1.00M | 36.41% | ↗ |
| 106 | 2012 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 103.5K | — | — | 649.1K | 44.6K | 4.3K | 801.6K | 80.98% | ↗ |
| 107 | 2012 | Andrew J. Grethlein, Ph.D. Executive Vice President, Development and Technical Operations | 103.5K | — | — | 649.1K | 44.6K | 4.3K | 801.6K | 80.98% | ↗ |
| 108 | 2012 | Melissa A. Kelly Behrs Executive Vice President, Bus. Dev. and Portfolio Alliance Management | 330.0K | — | — | 243.6K | 132.0K | 36.3K | 741.9K | 32.84% | ↗ |
| 109 | 2012 | Melissa A. Kelly Behrs Executive Vice President, Portfolio and Alliance Management | 330.0K | — | — | — | 132.0K | 36.3K | 741.9K | 0.00% | ↗ |
| 110 | 2012 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 259.0K | — | — | 174.6K | 114.7K | 30.5K | 578.8K | 30.17% | ↗ |
| 111 | 2012 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 259.0K | — | — | 174.6K | 114.7K | 30.5K | 578.8K | 30.17% | ↗ |
| 112 | 2011 | David L. Greenwood Former President, and Chief Financial Officer | 491.3K | 235.8K | 967.9K | — | — | 794.3K | 3.15M | 30.74% | ↗ |
| 113 | 2011 | Jane S. Lebkowski, Ph.D. Former Senior Vice President and Chief Scientific Officer | 335.0K | 107.2K | 416.2K | — | — | 405.2K | 1.39M | 29.96% | ↗ |
| 114 | 2011 | John A. Scarlett, M.D. President and Chief Executive Officer | 141.7K | — | — | — | — | 12.1K | 1.32M | 0.00% | ↗ |
| 115 | 2011 | John A. Scarlett, M.D. President and Chief Executive Officer | 141.7K | — | — | — | — | 12.1K | 1.32M | 0.00% | ↗ |
| 116 | 2011 | Thomas B. Okarma, Ph.D., M.D Former President and Chief Executive Officer | 56.6K | — | — | — | — | 1.09M | 1.15M | 0.00% | ↗ |
| 117 | 2011 | David J. Earp, J.D., Ph.D. Senior Vice President, Corporate Transactions, and Chief Legal Officer | 325.0K | 109.2K | 392.9K | — | — | 37.4K | 990.0K | 39.69% | ↗ |
| 118 | 2011 | Katharine E. Spink, Ph.D. | 296.1K | 92.8K | 116.3K | — | — | 353.7K | 984.3K | 11.81% | ↗ |
| 119 | 2011 | F.R.C.Path. Executive Vice President, RD and Chief Medical Officer | 400.0K | — | 174.4K | 188.2K | 156.6K | 43.2K | 962.3K | 37.67% | ↗ |
| 120 | 2011 | Stephen M. Kelsey, M.D., F.R.C.P, F.R.C.Path., Executive Vice President, Head of RD, and Chief Medical Officer | 400.0K | 156.6K | 174.4K | — | — | 43.2K | 962.3K | 18.12% | ↗ |
| 121 | 2011 | Melissa A. Kelly Behrs Executive Vice President, Portfolio and Alliance Management | 320.0K | — | 238.3K | — | 107.5K | 39.4K | 830.7K | 28.69% | ↗ |
| 122 | 2011 | Melissa A. Behrs Senior Vice President, Strategic Portfolio Management, Product | 320.0K | 107.5K | 238.3K | — | — | 39.4K | 830.7K | 28.69% | ↗ |
| 123 | 2011 | Olivia K. Bloom Executive Vice President, Finance, Chief Financial Officer and Treasurer | 211.0K | — | 210.3K | — | 71.3K | 30.3K | 648.3K | 32.43% | ↗ |
| 124 | 2010 | Thomas B. Okarma, Ph.D., M.D Former President and Chief Executive Officer | 535.0K | 283.8K | 666.8K | — | — | 16.4K | 1.79M | 37.26% | ↗ |
| 125 | 2010 | David L. Greenwood Former President, and Chief Financial Officer | 415.0K | 165.1K | 556.0K | — | — | 38.5K | 1.39M | 39.99% | ↗ |
| 126 | 2010 | President, Interim Chief Executive Officer and Chief Financial Officer | 415.0K | 165.1K | 556.0K | — | — | 38.5K | 1.39M | 39.99% | ↗ |
| 127 | 2010 | Stephen M. Kelsey, M.D., F.R.C.P, F.R.C.Path., Executive Vice President, Head of RD, and Chief Medical Officer | 400.0K | 159.1K | 556.0K | — | — | 36.7K | 1.37M | 40.66% | ↗ |
| 128 | 2010 | Executive Vice President, Chief Medical Officer, Oncology | 400.0K | 159.1K | 556.0K | — | — | 36.7K | 1.37M | 40.66% | ↗ |
| 129 | 2010 | F.R.C.Path. Executive Vice President, RD and Chief Medical Officer | 400.0K | — | 556.0K | 215.6K | 159.1K | 36.7K | 1.37M | 56.43% | ↗ |
| 130 | 2010 | Jane S. Lebkowski, Ph.D. Former Senior Vice President and Chief Scientific Officer | 335.0K | 118.5K | 489.9K | — | — | 35.8K | 1.12M | 43.62% | ↗ |
| 131 | 2010 | Senior Vice President, Chief Scientific Officer Cell Therapies | 335.0K | 118.5K | 489.9K | — | — | 35.8K | 1.12M | 43.62% | ↗ |
| 132 | 2010 | Melissa A. Behrs Senior Vice President, Oncology Therapeutic Development | 320.0K | 113.2K | 400.5K | — | — | 38.2K | 1.04M | 38.35% | ↗ |
| 133 | 2010 | Melissa A. Behrs Senior Vice President, Strategic Portfolio Management, Product | 320.0K | 113.2K | 400.5K | — | — | 38.2K | 1.04M | 38.35% | ↗ |
| 134 | 2010 | David J. Earp, J.D., Ph.D. Senior Vice President, Corporate Transactions, and Chief Legal Officer | 325.0K | 114.9K | 400.5K | — | — | 36.2K | 1.02M | 39.25% | ↗ |
| 135 | 2009 | Thomas B. Okarma, Ph.D., M.D Former President and Chief Executive Officer | 535.0K | 282.5K | 717.2K | — | — | 15.7K | 3.10M | 23.12% | ↗ |
| 136 | 2009 | Thomas B. Okarma, Ph.D., M.D. President and Chief Executive Officer | 535.0K | 282.5K | 717.2K | — | — | 15.7K | 3.10M | 23.12% | ↗ |
| 137 | 2009 | President, Interim Chief Executive Officer and Chief Financial Officer | 415.0K | 164.3K | 570.5K | — | — | 36.8K | 1.79M | 31.82% | ↗ |
| 138 | 2009 | David L. Greenwood Executive Vice President, Chief Financial Officer | 415.0K | 164.3K | 570.5K | — | — | 36.8K | 1.79M | 31.82% | ↗ |
| 139 | 2009 | David L. Greenwood Former President, and Chief Financial Officer | 415.0K | 164.3K | 570.5K | — | — | 36.8K | 1.79M | 31.82% | ↗ |
| 140 | 2009 | Stephen M. Kelsey, M.D., F.R.C.P, F.R.C.Path., Executive Vice President, Head of RD, and Chief Medical Officer | 272.8K | 158.4K | 193.6K | — | — | 12.1K | 1.37M | 14.11% | ↗ |
| 141 | 2009 | Chief Medical Officer, Oncology | 272.8K | 158.4K | 193.6K | — | — | 12.1K | 1.37M | 14.11% | ↗ |
| 142 | 2009 | Executive Vice President, Chief Medical Officer, Oncology | 272.8K | 158.4K | 193.6K | — | — | 12.1K | 1.37M | 14.11% | ↗ |
| 143 | 2009 | Senior Vice President, Business Development and Chief Patent Counsel | 325.0K | 114.4K | 423.8K | — | — | 35.8K | 1.36M | 31.10% | ↗ |
| 144 | 2009 | David J. Earp, J.D., Ph.D. Senior Vice President, Corporate Transactions, and Chief Legal Officer | 325.0K | 114.4K | 423.8K | — | — | 35.8K | 1.36M | 31.10% | ↗ |
| 145 | 2009 | Jane S. Lebkowski, Ph.D. Former Senior Vice President and Chief Scientific Officer | 335.0K | 117.9K | 423.8K | — | — | 35.2K | 1.29M | 32.94% | ↗ |
| 146 | 2009 | Senior Vice President, Chief Scientific Officer Cell Therapies | 335.0K | 117.9K | 423.8K | — | — | 35.2K | 1.29M | 32.94% | ↗ |
| 147 | 2009 | Senior Vice President, Chief Scientific Officer Regenerative Medicine | 335.0K | 117.9K | 423.8K | — | — | 35.2K | 1.29M | 32.94% | ↗ |
| 148 | 2009 | Melissa A. Behrs Senior Vice President, Oncology Therapeutic Development | 320.0K | 112.6K | 423.8K | — | — | 37.1K | 1.14M | 37.07% | ↗ |
| 149 | 2009 | Melissa A. Behrs Senior Vice President, Strategic Portfolio Management, Product | 320.0K | 112.6K | 423.8K | — | — | 37.1K | 1.14M | 37.07% | ↗ |
| 150 | 2008 | Thomas B. Okarma, Ph.D., M.D. President and Chief Executive Officer | 535.0K | 280.9K | 198.5K | — | — | 14.5K | 1.82M | 10.92% | ↗ |
| 151 | 2008 | Thomas B. Okarma, Ph.D., M.D Former President and Chief Executive Officer | 535.0K | 280.9K | 198.5K | — | — | 14.5K | 1.82M | 10.92% | ↗ |
| 152 | 2008 | President, Interim Chief Executive Officer and Chief Financial Officer | 415.0K | 163.4K | 148.9K | — | — | 36.6K | 1.37M | 10.86% | ↗ |
| 153 | 2008 | David L. Greenwood Executive Vice President, Chief Financial Officer | 415.0K | 163.4K | 148.9K | — | — | 36.6K | 1.37M | 10.86% | ↗ |
| 154 | 2008 | Calvin B. Harley, Ph.D. Chief Scientific Officer, Telomerase Technologies, | 315.0K | 96.5K | 453.1K | — | — | 33.3K | 1.22M | 37.23% | ↗ |
| 155 | 2008 | Senior Vice President, Chief Scientific Officer Cell Therapies | 335.0K | 117.3K | 99.3K | — | — | 32.3K | 778.4K | 12.75% | ↗ |
| 156 | 2008 | Senior Vice President, Chief Scientific Officer Regenerative Medicine | 335.0K | 117.3K | 99.3K | — | — | 32.3K | 778.4K | 12.75% | ↗ |
| 157 | 2008 | Melissa A. Behrs Senior Vice President, Oncology Therapeutic Development | 320.0K | 112.0K | 99.3K | — | — | 34.0K | 696.7K | 14.25% | ↗ |
| 158 | 2008 | Senior Vice President, Business Development and Chief Patent Counsel | 325.0K | 113.8K | 99.3K | — | — | 32.4K | 672.9K | 14.75% | ↗ |
| 159 | 2007 | Thomas B. Okarma, Ph.D., M.D. President and Chief Executive Officer | 510.0K | 275.0K | 3.16M | — | — | 14.5K | 4.57M | 69.23% | ↗ |
| 160 | 2007 | David L. Greenwood Executive Vice President, Chief Financial Officer | 395.0K | 160.0K | 1.62M | — | — | 34.4K | 2.66M | 60.74% | ↗ |
| 161 | 2007 | Thomas B. Okarma, Ph.D., M.D. President and CEO | 510.0K | 275.0K | 993.0K | — | — | 14.5K | 2.46M | 40.35% | ↗ |
| 162 | 2007 | Senior Vice President, Business Development and Chief Patent Counsel | 310.0K | 112.0K | 1.27M | — | — | 27.9K | 2.02M | 62.81% | ↗ |
| 163 | 2007 | Senior Vice President, Chief Scientific Officer Regenerative Medicine | 320.0K | 115.0K | 1.20M | — | — | 32.2K | 1.97M | 60.94% | ↗ |
| 164 | 2007 | David L. Greenwood Executive Vice President, CFO | 395.0K | 160.0K | 523.8K | — | — | 34.4K | 1.55M | 33.82% | ↗ |
| 165 | 2007 | Business Development and Chief Patent Counsel | 310.0K | 112.0K | 420.3K | — | — | 27.9K | 1.18M | 35.68% | ↗ |
| 166 | 2007 | Senior Vice President, Regenerative Medicine | 320.0K | 115.0K | 399.0K | — | — | 32.2K | 1.15M | 34.70% | ↗ |
| 167 | 2007 | Alan B. Colowick, M.D., M.P.H. President, Oncology | 425.0K | 172.0K | 169.2K | — | — | 33.0K | 1.08M | 15.73% | ↗ |
| 168 | 2007 | Calvin B. Harley, Ph.D. Chief Scientific Officer, Telomerase Technologies, | 305.0K | 83.0K | 335.4K | — | — | 35.1K | 971.2K | 34.53% | ↗ |
| 169 | 2006 | Thomas B. Okarma, Ph.D., M.D. President and CEO | 475.0K | 256.5K | — | — | — | 13.2K | 1.42M | 0.00% | ↗ |
| 170 | 2006 | Thomas B. Okarma, Ph.D., M.D. President and Chief Executive Officer | 475.0K | 256.5K | — | — | — | 13.2K | 1.42M | 0.00% | ↗ |
| 171 | 2006 | President and CEO | 475.0K | — | — | — | 256.5K | 13.2K | 1.30M | 0.00% | ↗ |
| 172 | 2006 | David L. Greenwood Executive Vice President, Chief Financial Officer | 365.0K | 147.8K | — | — | — | 36.6K | 988.2K | 0.00% | ↗ |
| 173 | 2006 | David L. Greenwood Executive Vice President, CFO | 365.0K | 147.8K | — | — | — | 36.6K | 988.2K | 0.00% | ↗ |
| 174 | 2006 | Executive Vice President, CFO | 365.0K | — | — | — | 147.8K | 36.6K | 914.4K | 0.00% | ↗ |
| 175 | 2006 | Business Development and Chief Patent Counsel | 287.0K | 86.1K | — | — | — | 27.7K | 650.0K | 0.00% | ↗ |
| 176 | 2006 | Senior Vice President, Business Development and Chief Patent Counsel | 287.0K | 86.1K | — | — | — | 27.7K | 650.0K | 0.00% | ↗ |
| 177 | 2006 | Senior Vice President, Chief Scientific Officer Regenerative Medicine | 285.0K | 85.5K | — | — | — | 30.7K | 636.7K | 0.00% | ↗ |
| 178 | 2006 | Senior Vice President, Regenerative Medicine | 285.0K | 85.5K | — | — | — | 30.7K | 636.7K | 0.00% | ↗ |
| 179 | 2006 | Calvin B. Harley, Ph.D. Chief Scientific Officer, Telomerase Technologies, | 282.0K | 88.8K | — | — | — | 33.2K | 623.1K | 0.00% | ↗ |
| 180 | 2006 | Chief Patent Counsel | 287.0K | — | — | — | 86.1K | 27.7K | 600.3K | 0.00% | ↗ |
| 181 | 2006 | Regenerative Medicine | 285.0K | — | — | — | 85.5K | 30.7K | 591.7K | 0.00% | ↗ |
| 182 | 2006 | Chief Scientific Officer | 282.0K | — | — | — | 88.8K | 33.2K | 585.2K | 0.00% | ↗ |
| 183 | 2006 | Alan B. Colowick, M.D., M.P.H. President, Oncology | 88.5K | 224.3K | 31.5K | — | — | 6.5K | 401.6K | 7.84% | ↗ |
| 184 | 2005 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer, | 445.0K | 213.6K | — | — | — | — | 658.6K | 0.00% | ↗ |
| 185 | 2004 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer, | 441.0K | 255.0K | — | — | — | — | 696.0K | 0.00% | ↗ |
| 186 | 2004 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer, Senior Vice President of Business Development and Regenerative Medicine Vice President and Chief Scientific Officer | 441.0K | 251.4K | — | — | — | — | 692.4K | 0.00% | ↗ |
| 187 | 2004 | David J. Earp, J.D., Ph.D. Senior Vice President of Business Development and Regenerative Medicine Vice President and Chief Scientific Officer | 340.4K | 151.2K | — | — | — | — | 491.6K | 0.00% | ↗ |
| 188 | 2003 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer, Senior Vice President of Business Development and Regenerative Medicine Vice President and Chief Scientific Officer | 420.0K | 268.2K | — | — | — | 42.0K | 730.2K | 0.00% | ↗ |
| 189 | 2003 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer Vice President and Chief Scientific Officer Vice President of Intellectual Property Senior Vice President of Regenerative Medicine | 420.0K | 268.2K | — | — | — | 42.0K | 730.2K | 0.00% | ↗ |
| 190 | 2003 | David J. Earp, J.D., Ph.D. Senior Vice President of Business Development and Regenerative Medicine Vice President and Chief Scientific Officer | 310.0K | 153.0K | — | — | — | 31.0K | 494.1K | 0.00% | ↗ |
| 191 | 2002 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer, Senior Vice President of Business Development and Regenerative Medicine Vice President and Chief Scientific Officer | 420.0K | — | — | — | — | — | 420.0K | 0.00% | ↗ |
| 192 | 2002 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer | 420.0K | — | — | 305.0K | — | — | 420.0K | 72.62% | ↗ |
| 193 | 2002 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer Vice President and Chief Scientific Officer Vice President of Intellectual Property Senior Vice President of Regenerative Medicine | 420.0K | — | — | — | — | — | 420.0K | 0.00% | ↗ |
| 194 | 2002 | David L. Greenwood Chief Financial Officer, Treasurer and Senior Vice | 310.0K | — | — | 235.0K | — | 12.0K | 322.0K | 72.98% | ↗ |
| 195 | 2002 | Calvin B. Harley, Ph.D Vice President and Chief Scientific Office | 257.3K | — | — | 100.0K | — | 12.0K | 269.3K | 37.14% | ↗ |
| 196 | 2002 | David J. Earp, J.D., Ph.D Vice President of Intellectual Property | 243.8K | — | — | 101.0K | — | 11.0K | 254.8K | 39.64% | ↗ |
| 197 | 2002 | Jane S. Lebkowski, Ph.D Vice President of Regenerative Medicine | 235.4K | — | — | 106.0K | — | 11.0K | 246.4K | 43.02% | ↗ |
| 198 | 2001 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer Executive Vice President, Chief Financial Officer Vice President and Chief Scientific Officer Vice President of Intellectual Property Senior Vice President of Regenerative Medicine | 342.5K | 150.0K | — | — | — | — | 492.5K | 0.00% | ↗ |
| 199 | 2001 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer | 342.5K | 150.0K | — | 240.0K | — | — | 492.5K | 48.73% | ↗ |
| 200 | 2001 | David L. Greenwood Chief Financial Officer, Treasurer and Senior Vice | 275.0K | 75.4K | — | 155.0K | — | — | 350.4K | 44.24% | ↗ |
| 201 | 2001 | Calvin B. Harley, Ph.D Vice President and Chief Scientific Office | 245.0K | 46.1K | — | 85.0K | — | — | 291.1K | 29.20% | ↗ |
| 202 | 2001 | David J. Earp, J.D., Ph.D Vice President of Intellectual Property | 230.0K | 50.4K | — | 119.0K | — | — | 280.4K | 42.44% | ↗ |
| 203 | 2001 | Jane S. Lebkowski, Ph.D Vice President of Regenerative Medicine | 220.0K | 48.2K | — | 129.0K | — | — | 268.2K | 48.10% | ↗ |
| 204 | 2000 | Thomas B. Okarma, M.D., Ph.D. President and Chief Executive Officer | 300.0K | 95.0K | — | — | — | — | 395.0K | 0.00% | ↗ |
| 205 | 2000 | David L. Greenwood Chief Financial Officer, Treasurer and Senior Vice | 250.0K | 30.0K | — | — | — | — | 280.0K | 0.00% | ↗ |
| 206 | 2000 | Calvin B. Harley, Ph.D Vice President and Chief Scientific Office | 239.2K | 23.9K | — | — | — | — | 263.1K | 0.00% | ↗ |
| 207 | 2000 | David J. Earp, J.D., Ph.D Vice President of Intellectual Property | 205.0K | 24.6K | — | — | — | — | 229.6K | 0.00% | ↗ |
| 208 | 2000 | Jane S. Lebkowski, Ph.D Vice President of Regenerative Medicine | 180.0K | 36.0K | — | — | — | — | 216.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | 1M | — |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 810.6K | female |
| Harout Semerjian | Chief Executive Officer, President & Director | 526.4K | male |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | 485.3K | male |
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | 307.9K | male |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | — | female |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | — | male |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | — | female |
| Shannon Odam | Executive Vice President & Chief People Officer | — | female |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GERN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
